Chung Po Liu; Denial of Hearing; Final Debarment Order, 38696-38699 [2015-16561]
Download as PDF
38696
Federal Register / Vol. 80, No. 129 / Tuesday, July 7, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1951]
CHEMBIOMED, LTD.; Revocation of
U.S. License No. 0916
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
revocation of the biologics license (U.S.
License No. 0916) issued to
CHEMBIOMED, LTD. (CHEMBIOMED)
for the manufacture of Anti-A (Murine
Monoclonal), Anti-B (Murine
Monoclonal), Anti-Lea (Murine
Monoclonal) and Anti-Leb (Murine
Monoclonal). CHEMBIOMED did not
respond to a notice of opportunity for a
hearing on a proposal to revoke its
license.
SUMMARY:
The revocation of the biologics
license (U.S. License No. 0916) is
effective July 7, 2015.
FOR FURTHER INFORMATION CONTACT:
Jessica T. Walker, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240–
402–7911.
SUPPLEMENTARY INFORMATION:
FDA is revoking the biologics license
(U.S. License No. 0916) issued to
CHEMBIOMED, 9515 107th St., Rm.
401, Edmonton AB T5K 2C3, Canada,
for the manufacture of Anti-A (Murine
Monoclonal), Anti-B (Murine
Monoclonal), Anti-Lea (Murine
Monoclonal) and Anti-Leb (Murine
Monoclonal). Proceedings to revoke U.S.
License No. 0916 were initiated under
§ 601.5(b) (21 CFR 601.5(b)) because
FDA determined through various means
that a meaningful inspection of
CHEMBIOMED could not be conducted
because the manufacturer was no longer
in operation.
In a phone conversation that occurred
on July 7, 1992, a former CHEMBIOMED
employee informed FDA that
CHEMBIOMED was no longer in
business, had ceased the manufacture of
licensed products, and had also ceased
shipments of licensed products to the
United States.
In a letter dated June 16, 1995, FDA
requested from the Authorized Official
(Responsible Head) of CHEMBIOMED a
status update for the production of all
of the products for which
CHEMBIOMED held a U.S. license. This
letter requested that the firm notify FDA
tkelley on DSK3SPTVN1PROD with NOTICES
DATES:
VerDate Sep<11>2014
20:31 Jul 06, 2015
Jkt 235001
in writing of the firm’s status and also
informed the Authorized Official that in
the absence of a response to this letter
that FDA would take action to revoke
CHEMBIOMED’s U.S. license. FDA did
not receive a response to its letter dated
June 16, 1995.
In a certified, return-receipt letter
dated October 18, 1995, FDA requested
that the Authorized Official of
CHEMBIOMED inform FDA whether or
not the firm intended to pursue a
product license application supplement
request dated May 6, 1987. In the
October 18, 1995 letter, FDA also
informed the Authorized Official that
the product license application
supplement request had been placed in
the FDA inactive files. FDA did not
receive a response to its certified,
return-receipt letter dated October 18,
1995.
In a letter to CHEMBIOMED dated
December 19, 2012, FDA provided
notice of FDA’s intent to revoke U.S.
License No. 0916, and announced its
intent to offer an opportunity for a
hearing. FDA indicated that FDA
registrations for CHEMBIOMED
facilities have not been updated since
May 12, 1994. The letter also advised
the Authorized Official that, under
§ 601.5(b)(1)(i) and (ii) of FDA’s
regulations, proceedings for license
revocation may be instituted when FDA
finds that authorized FDA employees
have been unable to gain access to an
establishment for the purpose of
carrying out an inspection, or when the
manufacturing of a product has been
discontinued to an extent that a
meaningful inspection cannot be made
at the establishment. The December 19,
2012 letter to CHEMBIOMED, sent via
United Parcel Service, was returned as
undeliverable.
In addition, Health Canada advised
FDA that CHEMBIOMED was no longer
in operation, according to the Industry
Canada Web site: www.ic.gc.ca.
CHEMBIOMED (Corporation No.
0228176 and Business No.
100938521RC0001 under the governing
legislation of the Canada Business
Corporations Act) was issued a
Certificate of Incorporation on August
15, 1977, and later was issued a
Certificate of Dissolution on March 17,
1999.
Under § 12.21(b) (21 CFR 12.21(b)),
FDA published in the Federal Register
of January 14, 2015 (80 FR 1917), a
notice of opportunity for a hearing
(NOOH) on a proposal to revoke the
biologics license (U.S. License No. 0916)
issued to CHEMBIOMED for the
manufacture of Anti-A (Murine
Monoclonal), Anti-B (Murine
Monoclonal), Anti-Lea (Murine
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Monoclonal) and Anti-Leb (Murine
Monoclonal). In the NOOH, FDA
explained that the proposed license
revocation was based on information
that the firm was no longer in operation
and the manufacture of its licensed
products has been discontinued. FDA
also noted in the NOOH that the
documentation in support of the license
revocation had been placed on file with
the Division of Dockets Management
under the docket number found in
brackets in the heading of the notice.
The NOOH provided the firm 30 days
to submit an electronic or written
request for a hearing and 60 days to
submit any data and information
justifying a hearing. The NOOH
provided other interested persons with
60 days to submit electronic or written
comments on the proposed revocation.
The firm did not respond within the 30day time period with an electronic or
written request for a hearing, and under
§ 12.21(b), the 30-day time period
prescribed in the NOOH may not be
extended. No comments from other
interested persons were received within
the 60-day time period.
Accordingly under 21 CFR 12.38,
section 351 of the Public Health Service
Act (42 U.S.C. 262), and under the
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Director and Deputy Director of the
Center for Biologics Evaluation and
Research (FDA Staff Manual Guide
1410.203), the biologics license (U.S.
License No. 0916) issued to
CHEMBIOMED, LTD. for the
manufacture of Anti-A (Murine
Monoclonal), Anti-B (Murine
Monoclonal), Anti-Lea (Murine
Monoclonal) and Anti-Leb (Murine
Monoclonal) is revoked, effective July 7,
2015.
Dated: June 30, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–16562 Filed 7–6–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0169]
Chung Po Liu; Denial of Hearing; Final
Debarment Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is denying Chung
SUMMARY:
E:\FR\FM\07JYN1.SGM
07JYN1
Federal Register / Vol. 80, No. 129 / Tuesday, July 7, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
Po Liu’s (Liu) request for a hearing and
is issuing an order under the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) debarring Liu for 5 years
from importing articles of food or
offering such articles for importation
into the United States. FDA bases this
order on a finding that Liu was
convicted of a felony for conduct
relating to the importation of an article
of food into the United States. In
determining the appropriateness and
period of Liu’s debarment, FDA has
considered the relevant factors listed in
the FD&C Act. Liu has failed to file with
the Agency information and analysis
sufficient to create a basis for a hearing
concerning this action.
DATES: This order is effective July 7,
2015.
ADDRESSES: Submit applications for
termination of debarment to the
Division of Dockets Management Branch
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Julie
Finegan, Office of Scientific Integrity,
Food and Drug Administration, 10903
New Hampshire Ave., Silver Spring, MD
20993, 301–796–8618.
SUPPLEMENTARY INFORMATION:
I. Background
On August 26, 2010, Chung Po Liu
pleaded guilty to the felony crime of
entering honey, a food, into the
commerce of the United States by means
of a false statement, in violation of 18
U.S.C. 542 and 2. Liu admitted that he
had caused his customs broker to
declare Thailand to be the country of
origin of one honey shipment, although
the majority of the honey originated in
China, and to declare the Philippines to
be the country of origin of a second
honey shipment, although the honey
originated in China. Liu admitted that,
in each instance, he had documents in
his possession establishing that the
honey originated in China, that the
declaration of country of origin was
false, and that he was without
reasonable cause to believe it was true.
Liu also admitted that the United States
began requiring the deposit of estimated
anti-dumping duties of between 183
percent and 221 percent on all nonexempt honey of Chinese origin
beginning in 2001. Liu did not deposit
estimated anti-dumping duties for either
of these two shipments of imported
honey. Liu also pleaded guilty to the
misdemeanor crime of introducing
adulterated food into interstate
commerce in violation of sections
301(a), 303(a)(1), and 402(a)(2)(C)(i) of
the FD&C Act (21 U.S.C. 331(a),
VerDate Sep<11>2014
20:31 Jul 06, 2015
Jkt 235001
333(a)(1), and 342(a)(2)(C)(i)). Liu
admitted that he had introduced honey
that contained the unsafe food additive
ciprofloxacin, an antibiotic, into
interstate commerce. On December 20,
2010, the U.S. District Court for the
Western District of Washington entered
a criminal judgment against Liu under
his guilty plea.
Section 306(b)(1)(C) of the FD&C Act
(21 U.S.C. 335a(b)(1)(C)) authorizes FDA
to debar a person from importing
articles of food or offering food for
importation into the United States based
on a finding, under section 306(b)(3) of
the FD&C Act, that the person was
convicted of a felony for conduct
relating to the importation of food into
the United States. By letter dated April
25, 2011, in accordance with section
306(i) of the FD&C Act and 21 CFR
10.50(c)(20) and 12.21(b), FDA, Office of
Regulatory Affairs (ORA) notified Liu
that the Agency proposed to debar him
for 5 years from importing any articles
of food or offering such articles for
importation into the United States and
offered an opportunity to request a
hearing on the proposed order of
debarment to resolve disputed issues of
material fact. ORA advised Liu that a
request for a hearing may not rest upon
mere allegations or denials, but must
present specific facts showing that there
is a genuine and substantial issue of fact
that requires a hearing.
In a letter dated May 24, 2011, Liu
requested a hearing on his proposed
debarment. On June 11, 2011, Liu
submitted materials in support of his
hearing request. In these materials,
which were submitted in accordance
with 21 CFR 12.22, Liu acknowledges
his felony conviction. However, he
urges FDA not to exercise its authority
to debar him based on that conviction.
In the alternative, he argues that any
debarment should be limited to the 1year period of supervised release that
the court ordered him to serve after his
release from custody after serving his
sentence of incarceration of 1 year and
1 day.
Under the authority delegated to him
by the Commissioner of Food and
Drugs, the Director of the Office of
Scientific Integrity (the Director) has
considered Liu’s submission. FDA will
grant a hearing only if the material
submitted shows that there is a genuine
and substantial issue of fact for
resolution at the hearing. Hearings will
not be granted on issues of policy or
law, on mere allegations, denials, or
general descriptions of positions and
contentions, or on data and information
insufficient to justify the factual
determination urged (see 21 CFR
12.24(b)). Based on this review, the
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
38697
Director has concluded that Liu has
failed to raise a genuine and substantial
issue of fact for resolution at a hearing
and that a hearing is not justified.
Accordingly, Liu’s request for a hearing
is denied, and FDA is issuing this notice
to explain the basis for this decision (see
21 CFR 12.24(a) and 12.28).
II. Arguments
Liu raises two primary arguments in
support of his hearing request. Liu first
contends generally that debarment is
‘‘unwarranted in law and without
justification by the facts in the case.’’ He
also urges that FDA should not debar
him due to his advanced age and ill
health, or, alternatively, that FDA
should debar him for a time period of
less than 5 years, the debarment period
proposed in the Notice of Opportunity
for Hearing.
Liu notes that, under section 306(b),
the decision whether to debar him is
committed to FDA’s discretion, and that
FDA is authorized to debar him ‘‘as a
result of conviction of certain crimes’’
(June 21 submission at 1). Indeed,
section 306(b)(3) of the FD&C Act states
that a person is subject to debarment if
the person has been convicted of a
felony for conduct relating to the
importation into the United States of
any food. Liu does not dispute that he
was convicted of a felony crime in
violation of 18 U.S.C. 542 and 2, or that
his conviction was based on conduct
relating to the importation of honey, a
food. In the plea agreement Liu signed,
which he does not now refute, he
admitted that: (1) He entered or
introduced, or attempted to enter or
introduce, into the commerce of the
United States, imported merchandise;
(2) he did so by means of any fraudulent
or false invoice, declaration, affidavit,
letter, paper, or by means of any false
statement, written or verbal; and (3) he
was without reasonable cause to believe
the truth of such statement or procured
the making of any such false statement
as to any matter material thereto
without reasonable cause to believe the
truth of such statement (Plea Agreement
at 2). He further admitted that this
conduct related to the importation of
honey, a food (see, for example, Plea
Agreement at 11–12, June 21 submission
at 2–3). Accordingly, Liu is subject to
debarment under section 306(b)(3) on
the basis of that felony conviction.
Since Liu’s felony conviction for
conduct relating to the importation into
the United States of honey establishes a
predicate from which FDA may choose
to exercise its authority to debar him,
Liu’s June 21 submission in support of
his request for a hearing attempts to
raise factual issues concerning the
E:\FR\FM\07JYN1.SGM
07JYN1
tkelley on DSK3SPTVN1PROD with NOTICES
38698
Federal Register / Vol. 80, No. 129 / Tuesday, July 7, 2015 / Notices
application of the factors in section
306(c)(3) that FDA is required to
consider in determining the
appropriateness and the period of
debarment. These are the applicable
criteria: (1) The nature and seriousness
of any offense involved; (2) the nature
and extent of management participation
in any offense involved, whether
corporate policies and practices
encouraged the offense, including
whether inadequate institutional
controls contributed to the offense; (3)
the nature and extent of voluntary steps
to mitigate the impact on the public of
any offense involved, including . . . full
cooperation with any investigations
(including the extent of disclosure to
appropriate authorities of all
wrongdoing) . . . and any other actions
taken to substantially limit potential or
actual adverse effects on the public
health; (4) whether the extent to which
changes in ownership, management, or
operations have corrected the causes of
any offense involved and provide
reasonable assurances that the offense
will not occur in the future; and (5)
prior convictions under the FD&C Act or
under other Acts involving matters
within the jurisdiction of FDA.
Significantly, the health and age of an
individual subject to debarment are not
included as factors relevant to FDA’s
exercise of the Agency’s debarment
authority. Although a defendant may
sometimes argue that poor health and
advanced age should be considered in
mitigation of punishment, debarment
under 21 U.S.C. 335a is not a punitive
sanction. Instead it is remedial in
purpose. (See DiCola v. FDA, 77 F.3d
504, 507 (D.C. Cir. 1996) (permanent
debarment of convicted individual is
not punishment, but instead is a remedy
to protect the integrity of the drug
industry and public confidence in that
industry); Bae v. Shalala, 44 F.3d 489,
493 (7th Cir. 1995) (purpose of statute
establishing debarment authority was to
restore consumer confidence in generic
drugs by eradicating widespread
corruption in generic drug approval
process).) In determining whether to
debar Liu, as well as the length of a term
of debarment, FDA acts to protect the
public health and not to punish Liu.
Because we are acting for this remedial,
not punitive, purpose, Liu’s arguments
concerning his health and age are not
relevant to this proceeding.
I address each of the relevant factors
in turn.
A. The Nature and Seriousness of the
Offense
Liu emphasizes that he was not
convicted of the charge for which he
was originally indicted, conspiracy to
VerDate Sep<11>2014
20:31 Jul 06, 2015
Jkt 235001
violate 18 U.S.C. 545 by conspiring to
enter goods into the United States
through false statement, and to smuggle
goods. He urges that conviction under
the original charge would have required
proof that he acted ‘‘knowingly and
intentionally’’ (June 21 submission at 3).
He devotes much of his submission to
his argument that he did not act
‘‘knowingly and intentionally.’’
According to Liu’s June 21 submission,
Liu’s accomplices, Yong Xiang Yan, the
owner of Changge Jixiang Bee Products,
Ltd. of Henan China, and Boa Zhong
Zhang, a vice-president and part owner
of Changge, established a scheme to
transship and import into the United
States Chinese honey, using Indigo
Distribution Corp. in the Philippines.
He disclaims knowledge of the nature
and extent of their operations (June 21
submission at 4).
However, these allegations are not
relevant. Liu’s conviction was not for
violating, or conspiring to violate, 18
U.S.C. 545. The offense that must be
considered is his felony violation of 18
U.S.C. 542 and 2, which was based on
Liu’s causing the false declarations to be
made even though he was without
reasonable cause to believe the truth of
such statements. Even in his June 21
submission, Liu expressly acknowledges
that he had documents in his possession
indicating that, as described in the Plea
Agreement and as charged in the
superseding information to which he
pleaded guilty, two shipments of honey
he imported actually originated in
China (June 21 submission at 3). He
leaves unchallenged the factual basis for
his conviction: That, without reasonable
cause to believe the truth of the
statements, he caused his customs
broker to falsely state that the shipments
originated in Thailand (December 20,
2006, shipment) and the Philippines
(February 14, 2007, shipment).
Although he dismisses these as a ‘‘few
emails . . . among many hundreds of
documents relating to the importation of
honey found in Mr. Liu’s house’’ (June
21 submission at 3), he fully admits that
these communications were in his
possession. Liu has raised no factual
issue for resolution at a hearing
concerning whether he acted without
reasonable cause to believe the truth of
the statements concerning where the
honey was produced.
We further note that the statement of
facts, which Liu admitted in his plea
agreement, provides additional
information concerning his actions
which demonstrate the financial motive
behind this offense. Had Liu instructed
his customs broker to declare the
country of origin as China, he and his
companies would have been responsible
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
for anti-dumping duties in the amount
of 221 percent of the value of the honey
(Plea Agreement at 11–12). Liu’s
misrepresentation was thus both
material and meaningful in the imports
process, and it could not have been lost
on Liu how important the country of
origin was in the context of the antidumping duties for Chinese honey.
Finally, I note that Liu’s conviction
did not rest on a single false statement.
Instead, he pleaded guilty to a
superseding information that included
false statements with respect to two
separate entries of imported Chinese
honey, 2 months apart. His conviction
did not rest on a single isolated
incident, but on a repeated violation.
Therefore, it is undisputed that Liu
was responsible for multiple material
false statements that resulted in the
avoidance of significant duties for the
importation of two shipments of honey
with a total declared value of $186,912.
As such, I agree with ORA’s evaluation
of this consideration and find that the
nature and seriousness of Liu’s felony
offense weighs strongly in favor of
debarment.
B. The Nature and Extent of
Management Participation in the
Offense
Next, I consider whether Liu’s
response raised specific facts showing
that there is a genuine and substantial
issue of fact that requires a hearing
concerning the nature and extent of
management participation in the
offense, including whether corporate
policies and practices encouraged the
offense, and whether inadequate
institutional controls contributed to the
offense.
In the Notice of Opportunity for a
Hearing, ORA stated, ‘‘As the owner of
the importing companies, you were
responsible for the accuracy of
declarations made to United States
customs officials. You were without
reasonable cause to believe the truth of
these declarations regarding the origins
of the honey. Further, you directly
profited from the domestic sale of the
imported honey.’’
Liu has not challenged these
statements, and all of the descriptions of
Liu’s actions in the June 21 submission
show him to act alone, as the individual
responsible for importing these two
shipments of honey. I agree with ORA
that, based upon these facts, the nature
and extent of Liu’s management
participation in the offense weighs in
favor of debarment.
E:\FR\FM\07JYN1.SGM
07JYN1
Federal Register / Vol. 80, No. 129 / Tuesday, July 7, 2015 / Notices
C. The Nature and Extent of Voluntary
Steps To Mitigate the Impact on the
Public
Next, I consider whether Liu has
raised specific facts showing that there
is a genuine and substantial issue of fact
that requires a hearing concerning the
nature and extent of voluntary steps to
mitigate the impact of his offense on the
public, including full cooperation with
any investigations (including the extent
of disclosure to appropriate authorities
of all wrongdoing) and any other actions
taken to substantially limit potential or
actual adverse effects on the public
health.
In the Notice of Opportunity for a
Hearing, ORA stated, ‘‘You took no
steps to mitigate the impact on the
public of your actions.’’ Liu has not
challenged this statement. As such, I
agree with ORA that the nature and
extent of Liu’s voluntary steps to
mitigate the impact to the public weighs
in favor of debarment.
D. The Impact of Changes in Ownership,
Management, or Operations
In the Notice of Opportunity for
Hearing, ORA determined that this
factor was not applicable for
consideration. Liu has not challenged
that determination.
tkelley on DSK3SPTVN1PROD with NOTICES
E. Prior Convictions Under the FD&C
Act or Related Acts
In the Notice of Opportunity for
Hearing, ORA acknowledged that the
Agency was unaware of any prior
convictions involving matters within
the jurisdiction of FDA. The lack of
previous violations of the FD&C Act or
related statutes by Liu weighs against
debarment.
III. Findings and Order
The Director of the Office of Scientific
Integrity, under section 306(b)(3)(A) of
the FD&C Act and under authority
delegated to him, finds that Liu has
been convicted of a felony for conduct
relating to the importation of food into
the United States. Accordingly, FDA
may debar Liu from importing articles of
food or offering such articles for import
into the United States for a period of not
more than 5 years.
I have considered the arguments
raised by Liu regarding the relevant
factors listed in section 306(c)(3) of the
FD&C Act and have determined that Liu
has raised no genuine and substantial
issues of fact that require resolution at
an evidentiary hearing. I have
considered the factors in section
306(c)(3) of the FD&C Act. The nature
and seriousness of Liu’s offense, Liu’s
management participation in the
offense, and the lack of any voluntary
VerDate Sep<11>2014
20:31 Jul 06, 2015
Jkt 235001
steps to mitigate the impact of the
offense weigh in favor of debarring.
Although Liu appears to have no prior
criminal convictions involving matters
within the jurisdiction of FDA, that
consideration does not counterbalance
to a sufficient degree the remaining
considerations to warrant decreasing the
period of debarment. Of particular note
is the nature and seriousness of the
offense, in light of the volume of honey
that was imported, the amount of duties
that were avoided, and the fact that false
statements were made with regard to
two shipments of honey. I agree with
ORA’s proposed period of debarment
and find that a debarment of 5 years is
appropriate.
As a result of the foregoing findings,
Liu is debarred for a period of 5 years
from importing articles of food or
offering such articles for import into the
United States, effective (see DATES).
Under section 301(cc) of the FD&C Act,
the importing or offering for import into
the United States of an article of food
by, with the assistance of, or at the
direction of Liu is a prohibited act.
Any application by Liu for
termination of debarment under section
306(d) of the FD&C Act should be
identified with Docket No. FDA–2011–
N–0169 and sent to the Division of
Dockets Management Branch (see
ADDRESSES). All such submissions are to
be filed in four copies. The public
availability of information in these
submissions is governed by 21 CFR
10.20(j). Publicly available submissions
may be seen in the Division of Dockets
Management Branch between 9 a.m. and
4 p.m., Monday through Friday. Persons
with access to the Internet may obtain
documents in the Docket at https://
www.regulations.gov.
Dated: June 25, 2015.
Nathan Doty,
Director, Office of Scientific Integrity.
[FR Doc. 2015–16561 Filed 7–6–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Advisory Council on Nurse
Education and Practice; Notice of
Meeting
In accordance with section
10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92–463), notice
is hereby given of the following meeting
of the National Advisory Council on
Nurse Education and Practice
(NACNEP).
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
38699
July 28 and 29, 2015, 8:30 a.m.–
5 p.m. EST.
ADDRESSES: This meeting will be via
Webinar Format. U.S. Department of
Health and Human Services, Health
Resources and Services Administration,
5600 Fishers Lane, Rockville, Maryland
20857.
FOR FURTHER INFORMATION CONTACT: For
additional information regarding
NACNEP, please contact Jeanne Brown,
Staff Assistant, National Advisory
Council on Nurse Education and
Practice, Parklawn Building, 5600
Fishers Lane, Rockville, Maryland
20857. The telephone number is: (301)
443–5688. The email is jbrown@
hrsa.gov.
SUPPLEMENTARY INFORMATION:
Status: This advisory council meeting
will be open to the public.
Purpose: The purpose of the 131st
National Advisory Council on Nurse
Education and Practice (NACNEP)
meeting is to provide advice and
recommendations on policy and
program development related to the role
of nursing in Interprofessional
Education (IPE) and Practice. The
purpose is to discuss existing IPE
models in an academic setting and the
intersect between education and
practice as it relates to Health Care
delivery reform. The goal of the meeting
is to solicit recommendations for IPE in
an academic setting and the intersect
important to IPE and practice. Strengths,
challenges, achievable solutions, and
replicable models required and/or
available to move from discussion to
action will be identified. Additionally,
the meeting will discuss topics for
future work of the council. This meeting
will conclude with a formulation of
recommendations and form the basis for
NACNEP’s mandated Thirteenth Annual
Report to the Secretary of the U.S.
Department of Health and Human
Services and Congress.
Agenda: A final agenda will be posted
on the NACNEP Web site 3 days prior
to the meeting. Agenda items are subject
to change as priorities dictate.
Further information regarding
NACNEP including the roster of
members, reports to Congress, and
minutes from previous meetings is
available at the NACNEP Web site.
Members of the public and interested
parties may request to participate in the
meeting by contacting Staff Assistant,
Jeanne Brown. Access to the meeting
will be granted on a first come, firstserved basis and space is limited. Public
participants may submit written
statements in advance of the scheduled
meeting. If you would like to provide
oral public comment during the meeting
DATES:
E:\FR\FM\07JYN1.SGM
07JYN1
Agencies
[Federal Register Volume 80, Number 129 (Tuesday, July 7, 2015)]
[Notices]
[Pages 38696-38699]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-16561]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0169]
Chung Po Liu; Denial of Hearing; Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is denying Chung
[[Page 38697]]
Po Liu's (Liu) request for a hearing and is issuing an order under the
Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Liu for 5
years from importing articles of food or offering such articles for
importation into the United States. FDA bases this order on a finding
that Liu was convicted of a felony for conduct relating to the
importation of an article of food into the United States. In
determining the appropriateness and period of Liu's debarment, FDA has
considered the relevant factors listed in the FD&C Act. Liu has failed
to file with the Agency information and analysis sufficient to create a
basis for a hearing concerning this action.
DATES: This order is effective July 7, 2015.
ADDRESSES: Submit applications for termination of debarment to the
Division of Dockets Management Branch (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Julie Finegan, Office of Scientific
Integrity, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993, 301-796-8618.
SUPPLEMENTARY INFORMATION:
I. Background
On August 26, 2010, Chung Po Liu pleaded guilty to the felony crime
of entering honey, a food, into the commerce of the United States by
means of a false statement, in violation of 18 U.S.C. 542 and 2. Liu
admitted that he had caused his customs broker to declare Thailand to
be the country of origin of one honey shipment, although the majority
of the honey originated in China, and to declare the Philippines to be
the country of origin of a second honey shipment, although the honey
originated in China. Liu admitted that, in each instance, he had
documents in his possession establishing that the honey originated in
China, that the declaration of country of origin was false, and that he
was without reasonable cause to believe it was true. Liu also admitted
that the United States began requiring the deposit of estimated anti-
dumping duties of between 183 percent and 221 percent on all non-exempt
honey of Chinese origin beginning in 2001. Liu did not deposit
estimated anti-dumping duties for either of these two shipments of
imported honey. Liu also pleaded guilty to the misdemeanor crime of
introducing adulterated food into interstate commerce in violation of
sections 301(a), 303(a)(1), and 402(a)(2)(C)(i) of the FD&C Act (21
U.S.C. 331(a), 333(a)(1), and 342(a)(2)(C)(i)). Liu admitted that he
had introduced honey that contained the unsafe food additive
ciprofloxacin, an antibiotic, into interstate commerce. On December 20,
2010, the U.S. District Court for the Western District of Washington
entered a criminal judgment against Liu under his guilty plea.
Section 306(b)(1)(C) of the FD&C Act (21 U.S.C. 335a(b)(1)(C))
authorizes FDA to debar a person from importing articles of food or
offering food for importation into the United States based on a
finding, under section 306(b)(3) of the FD&C Act, that the person was
convicted of a felony for conduct relating to the importation of food
into the United States. By letter dated April 25, 2011, in accordance
with section 306(i) of the FD&C Act and 21 CFR 10.50(c)(20) and
12.21(b), FDA, Office of Regulatory Affairs (ORA) notified Liu that the
Agency proposed to debar him for 5 years from importing any articles of
food or offering such articles for importation into the United States
and offered an opportunity to request a hearing on the proposed order
of debarment to resolve disputed issues of material fact. ORA advised
Liu that a request for a hearing may not rest upon mere allegations or
denials, but must present specific facts showing that there is a
genuine and substantial issue of fact that requires a hearing.
In a letter dated May 24, 2011, Liu requested a hearing on his
proposed debarment. On June 11, 2011, Liu submitted materials in
support of his hearing request. In these materials, which were
submitted in accordance with 21 CFR 12.22, Liu acknowledges his felony
conviction. However, he urges FDA not to exercise its authority to
debar him based on that conviction. In the alternative, he argues that
any debarment should be limited to the 1-year period of supervised
release that the court ordered him to serve after his release from
custody after serving his sentence of incarceration of 1 year and 1
day.
Under the authority delegated to him by the Commissioner of Food
and Drugs, the Director of the Office of Scientific Integrity (the
Director) has considered Liu's submission. FDA will grant a hearing
only if the material submitted shows that there is a genuine and
substantial issue of fact for resolution at the hearing. Hearings will
not be granted on issues of policy or law, on mere allegations,
denials, or general descriptions of positions and contentions, or on
data and information insufficient to justify the factual determination
urged (see 21 CFR 12.24(b)). Based on this review, the Director has
concluded that Liu has failed to raise a genuine and substantial issue
of fact for resolution at a hearing and that a hearing is not
justified. Accordingly, Liu's request for a hearing is denied, and FDA
is issuing this notice to explain the basis for this decision (see 21
CFR 12.24(a) and 12.28).
II. Arguments
Liu raises two primary arguments in support of his hearing request.
Liu first contends generally that debarment is ``unwarranted in law and
without justification by the facts in the case.'' He also urges that
FDA should not debar him due to his advanced age and ill health, or,
alternatively, that FDA should debar him for a time period of less than
5 years, the debarment period proposed in the Notice of Opportunity for
Hearing.
Liu notes that, under section 306(b), the decision whether to debar
him is committed to FDA's discretion, and that FDA is authorized to
debar him ``as a result of conviction of certain crimes'' (June 21
submission at 1). Indeed, section 306(b)(3) of the FD&C Act states that
a person is subject to debarment if the person has been convicted of a
felony for conduct relating to the importation into the United States
of any food. Liu does not dispute that he was convicted of a felony
crime in violation of 18 U.S.C. 542 and 2, or that his conviction was
based on conduct relating to the importation of honey, a food. In the
plea agreement Liu signed, which he does not now refute, he admitted
that: (1) He entered or introduced, or attempted to enter or introduce,
into the commerce of the United States, imported merchandise; (2) he
did so by means of any fraudulent or false invoice, declaration,
affidavit, letter, paper, or by means of any false statement, written
or verbal; and (3) he was without reasonable cause to believe the truth
of such statement or procured the making of any such false statement as
to any matter material thereto without reasonable cause to believe the
truth of such statement (Plea Agreement at 2). He further admitted that
this conduct related to the importation of honey, a food (see, for
example, Plea Agreement at 11-12, June 21 submission at 2-3).
Accordingly, Liu is subject to debarment under section 306(b)(3) on the
basis of that felony conviction.
Since Liu's felony conviction for conduct relating to the
importation into the United States of honey establishes a predicate
from which FDA may choose to exercise its authority to debar him, Liu's
June 21 submission in support of his request for a hearing attempts to
raise factual issues concerning the
[[Page 38698]]
application of the factors in section 306(c)(3) that FDA is required to
consider in determining the appropriateness and the period of
debarment. These are the applicable criteria: (1) The nature and
seriousness of any offense involved; (2) the nature and extent of
management participation in any offense involved, whether corporate
policies and practices encouraged the offense, including whether
inadequate institutional controls contributed to the offense; (3) the
nature and extent of voluntary steps to mitigate the impact on the
public of any offense involved, including . . . full cooperation with
any investigations (including the extent of disclosure to appropriate
authorities of all wrongdoing) . . . and any other actions taken to
substantially limit potential or actual adverse effects on the public
health; (4) whether the extent to which changes in ownership,
management, or operations have corrected the causes of any offense
involved and provide reasonable assurances that the offense will not
occur in the future; and (5) prior convictions under the FD&C Act or
under other Acts involving matters within the jurisdiction of FDA.
Significantly, the health and age of an individual subject to
debarment are not included as factors relevant to FDA's exercise of the
Agency's debarment authority. Although a defendant may sometimes argue
that poor health and advanced age should be considered in mitigation of
punishment, debarment under 21 U.S.C. 335a is not a punitive sanction.
Instead it is remedial in purpose. (See DiCola v. FDA, 77 F.3d 504, 507
(D.C. Cir. 1996) (permanent debarment of convicted individual is not
punishment, but instead is a remedy to protect the integrity of the
drug industry and public confidence in that industry); Bae v. Shalala,
44 F.3d 489, 493 (7th Cir. 1995) (purpose of statute establishing
debarment authority was to restore consumer confidence in generic drugs
by eradicating widespread corruption in generic drug approval
process).) In determining whether to debar Liu, as well as the length
of a term of debarment, FDA acts to protect the public health and not
to punish Liu. Because we are acting for this remedial, not punitive,
purpose, Liu's arguments concerning his health and age are not relevant
to this proceeding.
I address each of the relevant factors in turn.
A. The Nature and Seriousness of the Offense
Liu emphasizes that he was not convicted of the charge for which he
was originally indicted, conspiracy to violate 18 U.S.C. 545 by
conspiring to enter goods into the United States through false
statement, and to smuggle goods. He urges that conviction under the
original charge would have required proof that he acted ``knowingly and
intentionally'' (June 21 submission at 3). He devotes much of his
submission to his argument that he did not act ``knowingly and
intentionally.'' According to Liu's June 21 submission, Liu's
accomplices, Yong Xiang Yan, the owner of Changge Jixiang Bee Products,
Ltd. of Henan China, and Boa Zhong Zhang, a vice-president and part
owner of Changge, established a scheme to transship and import into the
United States Chinese honey, using Indigo Distribution Corp. in the
Philippines. He disclaims knowledge of the nature and extent of their
operations (June 21 submission at 4).
However, these allegations are not relevant. Liu's conviction was
not for violating, or conspiring to violate, 18 U.S.C. 545. The offense
that must be considered is his felony violation of 18 U.S.C. 542 and 2,
which was based on Liu's causing the false declarations to be made even
though he was without reasonable cause to believe the truth of such
statements. Even in his June 21 submission, Liu expressly acknowledges
that he had documents in his possession indicating that, as described
in the Plea Agreement and as charged in the superseding information to
which he pleaded guilty, two shipments of honey he imported actually
originated in China (June 21 submission at 3). He leaves unchallenged
the factual basis for his conviction: That, without reasonable cause to
believe the truth of the statements, he caused his customs broker to
falsely state that the shipments originated in Thailand (December 20,
2006, shipment) and the Philippines (February 14, 2007, shipment).
Although he dismisses these as a ``few emails . . . among many hundreds
of documents relating to the importation of honey found in Mr. Liu's
house'' (June 21 submission at 3), he fully admits that these
communications were in his possession. Liu has raised no factual issue
for resolution at a hearing concerning whether he acted without
reasonable cause to believe the truth of the statements concerning
where the honey was produced.
We further note that the statement of facts, which Liu admitted in
his plea agreement, provides additional information concerning his
actions which demonstrate the financial motive behind this offense. Had
Liu instructed his customs broker to declare the country of origin as
China, he and his companies would have been responsible for anti-
dumping duties in the amount of 221 percent of the value of the honey
(Plea Agreement at 11-12). Liu's misrepresentation was thus both
material and meaningful in the imports process, and it could not have
been lost on Liu how important the country of origin was in the context
of the anti-dumping duties for Chinese honey.
Finally, I note that Liu's conviction did not rest on a single
false statement. Instead, he pleaded guilty to a superseding
information that included false statements with respect to two separate
entries of imported Chinese honey, 2 months apart. His conviction did
not rest on a single isolated incident, but on a repeated violation.
Therefore, it is undisputed that Liu was responsible for multiple
material false statements that resulted in the avoidance of significant
duties for the importation of two shipments of honey with a total
declared value of $186,912. As such, I agree with ORA's evaluation of
this consideration and find that the nature and seriousness of Liu's
felony offense weighs strongly in favor of debarment.
B. The Nature and Extent of Management Participation in the Offense
Next, I consider whether Liu's response raised specific facts
showing that there is a genuine and substantial issue of fact that
requires a hearing concerning the nature and extent of management
participation in the offense, including whether corporate policies and
practices encouraged the offense, and whether inadequate institutional
controls contributed to the offense.
In the Notice of Opportunity for a Hearing, ORA stated, ``As the
owner of the importing companies, you were responsible for the accuracy
of declarations made to United States customs officials. You were
without reasonable cause to believe the truth of these declarations
regarding the origins of the honey. Further, you directly profited from
the domestic sale of the imported honey.''
Liu has not challenged these statements, and all of the
descriptions of Liu's actions in the June 21 submission show him to act
alone, as the individual responsible for importing these two shipments
of honey. I agree with ORA that, based upon these facts, the nature and
extent of Liu's management participation in the offense weighs in favor
of debarment.
[[Page 38699]]
C. The Nature and Extent of Voluntary Steps To Mitigate the Impact on
the Public
Next, I consider whether Liu has raised specific facts showing that
there is a genuine and substantial issue of fact that requires a
hearing concerning the nature and extent of voluntary steps to mitigate
the impact of his offense on the public, including full cooperation
with any investigations (including the extent of disclosure to
appropriate authorities of all wrongdoing) and any other actions taken
to substantially limit potential or actual adverse effects on the
public health.
In the Notice of Opportunity for a Hearing, ORA stated, ``You took
no steps to mitigate the impact on the public of your actions.'' Liu
has not challenged this statement. As such, I agree with ORA that the
nature and extent of Liu's voluntary steps to mitigate the impact to
the public weighs in favor of debarment.
D. The Impact of Changes in Ownership, Management, or Operations
In the Notice of Opportunity for Hearing, ORA determined that this
factor was not applicable for consideration. Liu has not challenged
that determination.
E. Prior Convictions Under the FD&C Act or Related Acts
In the Notice of Opportunity for Hearing, ORA acknowledged that the
Agency was unaware of any prior convictions involving matters within
the jurisdiction of FDA. The lack of previous violations of the FD&C
Act or related statutes by Liu weighs against debarment.
III. Findings and Order
The Director of the Office of Scientific Integrity, under section
306(b)(3)(A) of the FD&C Act and under authority delegated to him,
finds that Liu has been convicted of a felony for conduct relating to
the importation of food into the United States. Accordingly, FDA may
debar Liu from importing articles of food or offering such articles for
import into the United States for a period of not more than 5 years.
I have considered the arguments raised by Liu regarding the
relevant factors listed in section 306(c)(3) of the FD&C Act and have
determined that Liu has raised no genuine and substantial issues of
fact that require resolution at an evidentiary hearing. I have
considered the factors in section 306(c)(3) of the FD&C Act. The nature
and seriousness of Liu's offense, Liu's management participation in the
offense, and the lack of any voluntary steps to mitigate the impact of
the offense weigh in favor of debarring. Although Liu appears to have
no prior criminal convictions involving matters within the jurisdiction
of FDA, that consideration does not counterbalance to a sufficient
degree the remaining considerations to warrant decreasing the period of
debarment. Of particular note is the nature and seriousness of the
offense, in light of the volume of honey that was imported, the amount
of duties that were avoided, and the fact that false statements were
made with regard to two shipments of honey. I agree with ORA's proposed
period of debarment and find that a debarment of 5 years is
appropriate.
As a result of the foregoing findings, Liu is debarred for a period
of 5 years from importing articles of food or offering such articles
for import into the United States, effective (see DATES). Under section
301(cc) of the FD&C Act, the importing or offering for import into the
United States of an article of food by, with the assistance of, or at
the direction of Liu is a prohibited act.
Any application by Liu for termination of debarment under section
306(d) of the FD&C Act should be identified with Docket No. FDA-2011-N-
0169 and sent to the Division of Dockets Management Branch (see
ADDRESSES). All such submissions are to be filed in four copies. The
public availability of information in these submissions is governed by
21 CFR 10.20(j). Publicly available submissions may be seen in the
Division of Dockets Management Branch between 9 a.m. and 4 p.m., Monday
through Friday. Persons with access to the Internet may obtain
documents in the Docket at https://www.regulations.gov.
Dated: June 25, 2015.
Nathan Doty,
Director, Office of Scientific Integrity.
[FR Doc. 2015-16561 Filed 7-6-15; 8:45 am]
BILLING CODE 4164-01-P